The Competition Appellate Tribunal has officially rejected an appeal by Reckitt Benckiser Pakistan Limited, upholding a massive thirty million rupee fine originally imposed by the Competition Commission of Pakistan. The landmark legal verdict penalizes the global consumer goods giant for executing misleading marketing campaigns that intentionally deceived the public regarding the actual medical classification of its flagship product, Strepsils. This regulatory showdown marks a critical turning point for corporate transparency and consumer rights within the country, proving that multinational brands face severe financial and legal consequences if their promotional strategies mask the true legal identity of their merchandise.
The legal dispute stems from a detailed corporate complaint alleging that the manufacturer deliberately designed its television, print, and digital advertisements to give everyday shoppers the false impression that the throat lozenge was an active, prescribed medication capable of curing sore throats and severe respiratory infections. However, the regulatory inquiry uncovered that while the product was historically registered as a drug, it was formally de-registered as a pharmaceutical over two decades ago and has since been legally classified as a non-medicated food item. The company capitalized on decades of built-up consumer trust by hiding this critical shift, burying the words non-medicated in microscopic font at the very bottom of the packaging while continuing to employ heavy medical imagery in its public campaigns.
Punjab Government Approves Extended Business Hours During Ramadan
By upholding this penalty under Section Ten of the Competition Act, the tribunal has directed the company to immediately halt all deceptive promotions and pay the multi-million rupee fine into the national treasury. Furthermore, the manufacturer must completely redesign its packaging to prominently display the non-medicated food status in bold English and Urdu text on the front of every box. This historic ruling sends a clear message to all fast-moving consumer goods and pharmaceutical companies operating across the country that masking food products as active medical treatments will result in immediate regulatory action and substantial financial penalties.
